Cargando…
Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates
Next-generation site-specific cysteine-based antibody–drug-conjugates (ADCs) broaden therapeutic index by precise drug-antibody attachments. However, manufacturing such ADCs for clinical validation requires complex full reduction and reoxidation processes, impacting product quality. To overcome this...
Autores principales: | Procopio-Melino, Renée, Kotch, Frank W., Prashad, Amar S., Gomes, Jose M., Wang, Wenge, Arve, Bo, Dawdy, Andrew, Chen, Lawrence, Sperry, Justin, Hosselet, Christine, He, Tao, Kriz, Ronald, Lin, Laura, Marquette, Kimberly, Tchistiakova, Lioudmila, Somers, Will, Rouse, Jason C., Zhong, Xiaotian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068625/ https://www.ncbi.nlm.nih.gov/pubmed/35508689 http://dx.doi.org/10.1038/s41598-022-11344-z |
Ejemplares similares
-
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
por: Ritchie, Michael, et al.
Publicado: (2013) -
A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography
por: Birdsall, Robert E, et al.
Publicado: (2015) -
Cysteine oxidation and disulfide formation in the ribosomal exit tunnel
por: Schulte, Linda, et al.
Publicado: (2020) -
Optimization of Tubulysin Antibody–Drug Conjugates:
A Case Study in Addressing ADC Metabolism
por: Tumey, L. Nathan, et al.
Publicado: (2016) -
Disulfide Bond Formation and Cysteine Exclusion in Gram-positive Bacteria
por: Daniels, Robert, et al.
Publicado: (2010)